The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2019 | Developing mantle cell lymphoma treatment for further success
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, Canada, speaking at the 17th International Workshop on Non-Hodgkin Lymphoma, Boston, MA, reflects on the progression of mantle cell lymphoma treatment and the possibilities for further improvement, through building on the use of novel agents such as BTK inhibitors and BCL2 inhibitors combined with frontline chemotherapy earlier on in the treatment of patients.
